FDA lifts hold on Finch’s mi­cro­bio­me crap­sule, as com­pa­ny looks to right ship

Finch Ther­a­peu­tics’ lead pro­gram may fly again.

The mi­cro­bio­me com­pa­ny an­nounced Thurs­day that the FDA lift­ed a two-month hold on clin­i­cal tri­als for its ex­per­i­men­tal treat­ment for re­cur­rent C. diff, a po­ten­tial­ly fa­tal bac­te­r­i­al in­fec­tion. Al­though the com­pa­ny still has to take sev­er­al steps be­fore it can re­sume its piv­otal study, the lift re­moves an un­usu­al pan­dem­ic-re­lat­ed hur­dle for Finch as the biotech looks to get its first ther­a­py over the fin­ish line and sta­bi­lize a pre­car­i­ous fi­nan­cial sit­u­a­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER